A first-of-its-kind vaccine to prevent breast cancer has shown overwhelmingly favorable results in animal models, according to a study by researchers at the US Cleveland Clinic's Lerner Research Institute. The researchers - whose findings were published in the journal Nature Medicine on-line over the weekend - are now planning to conduct trials of the drug in humans, although they warn that it could be some years before the vaccine is widely available to people.
The researchers found that a single vaccination with the antigen alpha-lactalbumin prevents breast cancer tumors from forming in mice, while also inhibiting the growth of already existing tumors. Enrollment in human trials could begin next year. If successful, it would be the first vaccine to prevent breast cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze